Botulinum toxin A - Ipsen

Drug Profile

Botulinum toxin A - Ipsen

Alternative Names: AbobotulinumtoxinA; Azzalure; BoNT-A; BTX-A-HAC NG; Dysport; Dysport NG; Dysport RU; Dysport® Next Generation; Reloxin

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Health Protection Agency Porton Down; Ipsen Limited
  • Developer Biosintetica; Galderma; Ipsen Limited; Medicis Pharmaceutical Corporation; Valeant Pharmaceuticals International
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Torticollis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Blepharospasm; Equinus foot deformity; Facial-wrinkles; Fissure in ano; Glabellar lines; Hyperhidrosis; Muscle spasticity; Neurogenic bladder; Spasm; Torticollis
  • Phase III Overactive bladder; Urinary incontinence
  • Phase II Gilles de la Tourette's syndrome
  • Discontinued Pain

Most Recent Events

  • 14 Mar 2017 Registered for Muscle spasticity (In adults) in Canada (IM)
  • 14 Mar 2017 Registered for Torticollis in Canada (IM)
  • 01 Dec 2016 Ipsen completes a phase III trial in Glabellar lines in Germany, France and United Kingdom (NCT02493946)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top